Can-Fite Biopharma (CANF) vs Enlivex (ENLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Can-Fite Biopharma is the larger company by market cap ($5.8 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | ENLV |
|---|---|---|
| Share price | $1.90 | $0.254 |
| Market cap | $5.76M | $5.06M |
| 1-day change | -5.00% | -8.30% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-13.23 | $494.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $27.15 |
| 52-week low | $1.90 | $0.224 |
| Distance from 52-week high | -84.68% | -99.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +321.05% | +31396.06% |
| Average volume | 388.00K | 945.30K |
| Shares outstanding | 3.03M | 19.91M |
| Employees | 5 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
CANF vs ENLV FAQ
Which is bigger, Can-Fite Biopharma or Enlivex?
Can-Fite Biopharma (CANF) is larger, with a market capitalization of $5.76M compared with $5.06M for Enlivex (ENLV).
Are Can-Fite Biopharma and Enlivex in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.